SCHEMBL7536110

SCHEMBL7536110

CCOC(=O)C(=O)Cc1ccc(C)c(C)c1

nearest known ligand 0.45

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CTDSP1 Q9GZU7 1/20 0.45
ALDH1A1 P00352 4/20 0.44
KMT2A Q03164 7/20 0.41
MEN1 O00255 6/20 0.41
GAA P10253 2/20 0.41
MAPT P10636 2/20 0.41
KDM4E B2RXH2 1/20 0.41
RIOK2 Q9BVS4 1/20 0.41
LMNA P02545 4/20 0.40
HTT P42858 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
POLB P06746 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7636607 0.84 ALDH1A1 (0.51) ALDH1A1KMT2AMEN1GAAMAPT
SCHEMBL7642808 0.83 ALDH1A1 (0.47) ALDH1A1KMT2AMEN1GAAMAPT
SCHEMBL13492095 0.82 MEN1 (0.49) ALDH1A1KMT2AMEN1GAAMAPT
SCHEMBL7641457 0.80 KMT2A (0.53) CTDSP1KMT2AMEN1GAAMAPT
SCHEMBL7642351 0.80 CTDSP1 (0.49) CTDSP1ALDH1A1KMT2AMEN1GAA
SCHEMBL7640114 0.80 ALDH1A1 (0.42) ALDH1A1KMT2AMEN1GAAMAPT
SCHEMBL7640320 0.80 TSHR (0.57) CTDSP1ALDH1A1KMT2AGAAMAPT
SCHEMBL7641749 0.80 ALDH1A1 (0.48) CTDSP1ALDH1A1KMT2AMEN1GAA
SCHEMBL7639928 0.79 GAA (0.50) CTDSP1KMT2AMEN1GAAMAPT
SCHEMBL8736585 0.79 ALDH1A1 (0.53) ALDH1A1KMT2AMEN1GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors ABBOTT LABORATORIES 2002-07-11 US disclosed
WO-2002022576-A2 3-SUBSTITUTED INDOLE CARBOHYDRAZIDES USEFUL AS CELL PROLIFERATION AND ANGIOGENESIS INHIBITORS ABBOTT LABORATORIES (US) 2002-03-21 WO disclosed
US-6348617-B1 REACTING PYRUVIC ACID COMPOUND IN WATER WITH AMMONIUM OR ALKALI METAL BISULFITE TO GIVE AQUEOUS SOLUTION OF BISULFITE ADDUCT, ISOLATING BY PHASE SEPARATION, OPTIONALLY USING HYDROPHOBIC SOLVENT, CONTACTING WITH ACID TO DECOMPOSE ADDUCT SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-02-19 US disclosed
US-6323228-B1 INHIBITING ANGIOGENESIS IN A MAMMAL IN RECOGNIZED NEED OF SUCH TREATMENT COMPRISING ADMINISTERING TO THE MAMMAL WITH INDOLE SUBSTITUTED WITH HYDRAZIDES ABBOTT LABORATORIES 2001-11-27 US disclosed
EP-0937703-A1 METHOD FOR PURIFYING PYRUVIC ACID COMPOUNDS SUMITOMO CHEMICAL COMPANY LIMITED (JP) 1999-08-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors MKI67, FLT4, IDO1 CTDSP1 2420/4885ALDH1A1 98/4885KMT2A 2765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.